TRADING UPDATES: MaxCyte strikes deal; Barkby sells Workshop
1st Aug 2023 14:26
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - MaxCyte Inc on Monday said it signed a strategic platform licence with Vittoria Biotherapeutics to advance cellular therapies. Read More
(Alliance News) - MaxCyte Inc on Thursday said it has signed a strategic platform license with Lyell Immunopharma Inc, a clinical stage T cell reprogramming company. Read More
(Alliance News) - MaxCyte Inc on Thursday reported a widened operating loss in the first quarter of 2023 as revenue fell and costs were higher. Read More
MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Signs a strategic platform license with Walking Fish Therapeutics Inc, a biotechnology company that is "rapidly advancing B cell-based therapeutics." Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees, clinical milestone payments and sales-based payments. Read More
MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Non-Executive Chair Richard Douglas buys 80,000 shares at average USD4.32, worth USD345,480, on Wednesday. Now has 100,000 shares, a 0.1% stake. Read More
(Alliance News) - MaxCyte Inc on Tuesday said it appointed Douglas Swirsky as its new chief financial officer, effective immediately. Read More
(Alliance News) - MaxCyte Inc on Thursday said revenue was up by a third in 2022, as it expects further growth in 2023. Read More
MaxCyte Inc - Maryland, US-based cell-engineering focused company - Forms new scientific advisory board that will reflect on research in molecular design and cell engineering and gain an understanding of translational development, in order to leverage the benefits of impactful discoveries for therapeutic applications. Board will include scientists, Oliver Rando, Marcela Maus, Avery Posey and Nako Nakatsuka. Read More
(Alliance News) - MaxCyte Inc on Tuesday announced a higher revenue for 2022, and said it anticipates revenue to grow further during 2023. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - MaxCyte Inc on Wednesday said it signed a strategic platform licence with biotechnology company Catamaran Bio Inc. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
MaxCyte Inc - Gaithersburg, Maryland-based platform for cell-based research - Says second quarter revenue grew 35% year-on-year to USD9.6 million from USD7.1 million, "driven by strong growth in the cell therapy market; core business revenues grew 45% led by revenue from cell therapy customers which increased 61%, with drug discovery revenues growing by 4%", the firm says. Net loss for the quarter widens to USD8.3 million from US4.4 million. For the first half as a whole, revenue rises 56% year-on-year to USD21.2 million from USD13.6 million, as net loss widens slightly to USD12.3 million from USD11.5 million. Expects core business revenue in full year to grow approximately 30%. Continues to expect SPL Program-related revenue to be around USD4 million for the year. Says is making investments to drive revenue growth, and expand applications for its technology. Read More
MaxCyte Inc - Gaithersburg, Maryland-based platform for cell-based research - Signs a strategic platform license agreement with Korean chemical company LG Chem Ltd, a subsidiary of LG Corp. Explains that the deal gives LG non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. MaxCyte will receive platform licensing fees and programme related revenue. Read More